<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175596">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809783</url>
  </required_header>
  <id_info>
    <org_study_id>A4091016</org_study_id>
    <nct_id>NCT00809783</nct_id>
  </id_info>
  <brief_title>Extension Study Of Tanezumab In Osteoarthritis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Long Term Study Of The Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was terminated on 27 October 2010 following a US FDA clinical hold for tanezumab
      osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June
      2010 for potential safety issues.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematology</measure>
    <time_frame>112 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>112 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Chemistry</measure>
    <time_frame>112 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>112 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Womac Pain</measure>
    <time_frame>112 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Womac Physical Function</measure>
    <time_frame>112 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Womac Stiffness</measure>
    <time_frame>112 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2147</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tanezumab 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tanezumab 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tanezumab 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>Tanezumab 10 mg</description>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
    <other_name>RN624</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>Tanezumab 5 mg</description>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
    <other_name>RN624</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>Tanezumab 2.5 mg</description>
    <arm_group_label>Tanezumab 2.5 mg</arm_group_label>
    <other_name>RN624</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have participated in previous (specific) Phase 3 trials of Tanezumab in
             osteoarthritis

        Exclusion Criteria:

          -  Willing to comply with scheduled visits and treatment plan Is medically fit to
             participate in the trial in the judgement of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091016&amp;StudyName=Extension%20Study%20Of%20Tanezumab%20In%20Osteoarthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 2, 2011</lastchanged_date>
  <firstreceived_date>December 16, 2008</firstreceived_date>
  <firstreceived_results_disposition_date>November 2, 2011</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tanezumab OA arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
